BioCurie

What BioCurie does

BioCurie is a Wilmington, Delaware-based TechBio company building an artificial-intelligence software platform called ENGINE (ENabling Genomic Engineering) that targets cell and gene therapy manufacturing. The platform combines computational modeling with machine learning to replace traditional trial-and-error process development, addressing manufacturing bottlenecks that limit scalability and patient access to disease-modifying gene therapies — specifically high development costs, variable yields, and lengthy optimization cycles. The company's initial commercial focus is adeno-associated virus (AAV) gene therapy production, with a planned commercial release in late 2026.

The platform is being developed and validated through a consortium assembled in March 2026 that pairs BioCurie with Caring Cross (a nonprofit focused on cell and gene therapy access), St. Jude Children's Research Hospital (clinical and pediatric gene therapy expertise), Center for Breakthrough Medicines / SK pharmteco Cell & Gene US (commercial CDMO perspective), and University City Science Center (regional innovation-ecosystem support). The company's primary disclosed capital event is an up to $9.3 million award from the ARPA-H Health Science Futures Office, announced in February 2026, to fund ENGINE development.

BioCurie's go-to-market is B2B enterprise, targeting pharmaceutical and biotech manufacturers developing gene therapies through direct enterprise sales. Expected revenue mechanics are platform licensing/subscription to manufacturers supplemented by technology services delivered through consortium engagements. The company is pre-commercial, with 1–10 employees and no disclosed paying customers, pricing, or contract values at this stage.

Name

BioCurie

Legal name

BioCurie

Website

https://biocurie.ai

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

BioCurie is a Wilmington, Delaware-based TechBio company developing ENGINE, an AI-powered platform that uses computational modeling and machine learning to optimize gene and cell therapy manufacturing for pharmaceutical and biotech manufacturers.

Ownership category

akta.pro rank

Product category

AI Biomanufacturing Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Gene therapy manufacturing
• AI-driven bioprocessing
• Computational process optimization
• Cell and gene therapy software
• Biomanufacturing analytics

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Platform Licensing/Subscription: BioCurie is developing an AI-powered digital platform for scalable gene therapy manufacturing with planned commercial release for adeno-associated virus gene therapy production in late 2026. Revenue is expected to be generated through platform licensing to gene therapy manufacturers.
2. Technology Services: The company provides technology services to address manufacturing bottlenecks and aims to create a foundation for broader industry deployment through consortium partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioCurie is developing ENGINE, an AI-powered digital platform that combines computational modeling with machine learning to optimize gene therapy manufacturing processes. The platform replaces trial-and-error process development with in-silico modeling, targeting adeno-associated virus (AAV) gene therapy production. Planned commercial release is late 2026.

Product overview

BioCurie offers a single unified AI-powered digital platform called ENGINE (ENabling Genomic Engineering), designed to optimize gene therapy manufacturing processes. The platform combines computational modeling and machine learning to replace traditional trial-and-error process development, aiming to address manufacturing bottlenecks including high development costs, variable yields, and lengthy optimization cycles that limit scalability and patient access to gene therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• ENGINE AI-powered digital platform that replaces trial-and-error process development with computational modeling and simulation for scalable gene therapy manufacturing. Combines machine learning and advanced modeling to reduce development timelines, manufacturing costs, and production bottlenecks for adeno-associated virus gene therapies.

Quantifiable outcome

• Reduce development timelines for gene therapy manufacturing
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Caring CrosscoreStrategic or Co-development Partner · 12 March 2026Caring Cross is part of the ARPA-H funded consortium to validate and develop the ENGINE platform. As a nonprofit focused on advancing cell and gene therapy access, Caring Cross provides clinical and implementation expertise to ensure the platform addresses real-world manufacturing needs.
• St. Jude Children's Research HospitalcoreStrategic or Co-development Partner · 12 March 2026St. Jude Children's Research Hospital is a consortium partner providing research validation for the AI-powered gene therapy manufacturing platform. The partnership brings clinical research expertise and real-world pediatric gene therapy development needs to inform platform development.
• Center for Breakthrough Medicines (SK pharmteco Cell & Gene US)coreStrategic or Co-development Partner · 12 March 2026Center for Breakthrough Medicines serves as an industry validation partner representing commercial manufacturing perspective. Their involvement ensures the platform addresses real manufacturing operations and can scale to commercial production requirements.
• University City Science CentersupportingStrategic or Co-development Partner · 12 March 2026University City Science Center provides regional innovation ecosystem support and infrastructure for the consortium. They serve as a hub for connecting academic and industry partners in the Philadelphia region.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Cytiva (Danaher): Global leader in bioprocess equipment, consumables, and digital tools for cell and gene therapy manufacturing. Cytiva offers broad process development and manufacturing platforms and represents the incumbent bundle BioCurie would have to integrate with or compete against.
• Sartorius: Major bioprocess solutions provider with PAT/data analytics and cell & gene therapy manufacturing offerings. Sartorius is investing heavily in digital bioprocess capabilities, making it the most directly comparable incumbent building AI/ML into bioprocess workflows.
• Lonza: One of the world's largest CDMOs with significant cell and gene therapy manufacturing capacity. Lonza's scale and process know-how make it both a potential customer/partner and a long-term competitive threat if it internalizes AI optimization.
• Thermo Fisher Scientific: Provides bioprocess production services, analytics, and CDMO capabilities across cell and gene therapy. Its scale and ability to bundle manufacturing services with software make it a key potential competitor for process optimization offerings.

Emerging players

• Ginkgo Bioworks: Synthetic biology and AI-driven bioengineering platform expanding into cell engineering and bioprocess services. Ginkgo represents an adjacent TechBio model applying AI/automation to engineered biology, though its primary focus is organism engineering rather than gene therapy manufacturing.

Direct peers

• Vineti: Specialized software platform for cell and gene therapy orchestration, including manufacturing and supply chain workflows. Vineti targets the same buyer (gene therapy developers/CDMOs) with a complementary, software-only value proposition.
• Benchling: Cloud-based software platform for life sciences R&D and bioprocess development. Benchling serves biotech and gene therapy developers with informatics for process records, samples, and analytical data — a comparable software-first approach in the same buyer workflow.
• Dotmatics: Scientific informatics platform spanning lab data, bioprocess, and analytics. Dotmatics overlaps with BioCurie's intent to bring digital tools into gene therapy process development and manufacturing workflows.
• TetraScience: Cloud-native data platform for biopharma R&D and manufacturing, focused on harmonizing instrument and process data for AI/ML use cases. Directly comparable as a software layer enabling AI-driven bioprocess insight.
• DataHow: Specialist in data-driven modeling and AI for bioprocess development, particularly for cell culture and biologics. DataHow is one of the closest pure-play comparables for AI/ML-driven bioprocess process optimization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCurie